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Moderate to Severe Cancer Pain: Are We Taking Serious 
Action? The Opioid Prescribing Scenario in Portugal
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INTRODUCTION
 Pain is one of the most feared and distressing symptoms 
associated with cancer.1
 In Portugal, the incidence of malignant tumors has 
been increasing regularly, according to the 2017 National 
Program for Oncological Diseases.2 In 2016, cancer was 
the second basic cause of death in Portugal, representing 
24.7% of mortality.3
 Recently, a Portuguese study showed that of 371 
patients with cancer-related pain (CRP), 77% had moderate 
to severe pain, whose severity could be explained by 
the lower morphine equivalent daily dose prescribed.4 
Moreover, undertreatment of CRP was present in 25.6% of 
patients.5 There was an association between inadequacy 
of CRP treatment and absence of opioid prescriptions (p < 
0.001).5
ACCESS TO ADEQUATE PAIN TREATMENT
 Uncontrolled pain is a major public health concern. 
People with CRP ought to have access to appropriate pain 
assessment and treatment by adequately trained health 
care professionals.1,6
 The Declaration of Montreal states that access to pain 
management is a fundamental human right. Withholding 
pain treatment is profoundly wrong, leading to unnecessary 
suffering which is harmful.7
 According to the World Health Organization, in its 2011 
guidance document ‘Ensuring balance in national policies 
on controlled substances’, governments should ensure that 
all population groups, without discrimination, equally benefit 
from their policies on the availability and accessibility of 
controlled medicines for rational medical use. That has 
been established in Portugal. Some historical milestones 
confirm that. In 2003, the Directorate-General of Health 
safeguarded pain as the 5th vital sign and its assessment 
became mandatory. In 2004, the Portuguese Medical 
Association approved the ‘Competence in Pain Medicine’ 
and, in 2013, likewise, a ‘Competence in Palliative 
Medicine’ was agreed. In 2011, the Portuguese Ministry 
of Health launched Law 113/2011 announcing that all the 
consultations at Pain Clinics within the National Health 
Service were free of charge. In 2013, the National Strategic 
Pain Prevention and Control Plan was approved. In 2016, 
the legislation entitled  Portaria 331/2016 declared a new 
list of WHO-step III analgesics, reimbursable up to 90%, to 
be used in ambulatory patients with CRP.8 In 2017, the new 
National Programme for the Prevention and Control of Pain 
was launched.
OPIOID CONSUMPTION IN PORTUGAL
 Opioids are the pillar of the medical management of 
moderate to severe CRP.6
 Although extremely high rates of use of opioids exist in a 
few countries, namely in the USA, it should not be regarded 
as an ubiquitous problem.9
 Despite overcoming legislative impediments to 
availability, opioid consumption (OC) in Portugal is ranked 
among the lowest in western Europe.10
 There is a certain form of morphinofobia in Portugal.11 
Potential causes of undertreatment of CRP, which are 
attributable to health care providers, are both the fear of 
prescribing opioids and the lack of knowledge concerning 
optimal pain management.6 That was implied in a cross-
sectional study aiming at exploring the significance 
and attitudes concerning the use of morphine, with 412 
Portuguese participants (physicians and nurses) working at 
different settings (four hospitals and 10 community health 
centers).11 It showed that ‘morphine’ firstly suggested 
‘analgesia’ to only 32.9% of professionals. The reasons for 
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not using morphine were fear both of legal risks (56.3%) 
and of adverse side effects, such as somnolence-sedation 
(30.5%).11
 In a nationwide study, which included a representative 
sample of the Portuguese adult population (5094 
participants), the prevalence of OC in chronic pain was 
4.37% (95% confidence interval = 3.4 - 5.5), being 10.13% 
and 4.24% in cancer and non-cancer patients, respectively.9 
Strong opioids were prescribed to 0.17% of the patients. 
Pain severity was significantly associated with OC, however 
in multivariate modeling only pain-related disability remained 
associated to OC.9
 A Portuguese prospective observational study with 301 
advanced cancer patients referred to palliative care showed 
that 74% were on opioids, 42% had moderate to severe and 
35.2% had no pain at all. It found that moderate to severe 
CRP was associated with shorter time to death.12 Sample 
characteristics in the latter study were quite different 
from the ones found in the previously mentioned cross-
sectional Portuguese observational study4,5: patients were 
ambulatory, CRP was present in 100%, 83.3% had good 
performance status and 88.7% were on opioids, yet more 
than 2/3 of the sample still had moderate to severe CRP. 
Prescribed opioids were weak (73.3%), mainly tramadol, 
and rarely strong ones (15.4%).5 This was odd because 
firstly, patients were followed at a national cancer center; 
secondly, because in cancer patients low-dose morphine 
reduces pain intensity significantly compared with weak 
opioids, with a similar good tolerability and an earlier effect.13 
The role of tramadol is limited in moderate to severe CRP.14
 The Pain & Policy Studies Group, a WHO Collaborating 
Center, receives from the International Narcotics Control 
Board consumption data for six principal opioids used to 
treat moderate to severe pain.10 These data represent 
the amounts of opioids distributed for medical purposes 
to the ‘retail’ level in a country (i.e., to those institutions 
and programs that are licensed to dispense to patients, 
such as hospitals, nursing homes, pharmacies, hospices, 
palliative care programs, or medication assisted treatment 
programs).10 It combines OC both for cancer and non-
cancer pain, with no distinction between them.
 Recent data showed that OC in Portugal, not considering 
methadone use, was 84.27 morphine equivalent (ME).10 
This includes (in ME): morphine (4.46), oxycodone (1.06), 
fentanyl (70.94), hydromorphone (7.26) and pethidine 
(0.55). 
 For comparison purpose, in 2015, in Portugal, methadone 
use represented 97.87 ME, much more than other opioids, 
altogether, prescribed in the country. Methadone is a drug 
that has similar analgesic benefits to morphine and has a 
role in the management of CRP in adults. Other opioids 
such as morphine and fentanyl are more expensive than 
methadone, but they are far easier to manage.15 It is likely, 
that much, if not most, of the methadone in Portugal is used 
for medication assisted treatment of opioid dependence 
syndrome and, therefore, is not a good indication of a 
country’s capacity to relieve pain.10
 If we look at the global OC in Portugal, we end up with 
182.13 ME. This is less than the figures found, excluding 
methadone, in southern countries like Spain, in western 
countries like the Netherlands and Switzerland, and in 
northern countries like Norway and Sweden. All of these 
have OC ranging from 215 and 265 ME (methadone not 
considered).10 
 In 2015, out of 24 European countries analyzed, there 
were only six with fewer OC (excluding methadone) than 
Portugal: Croatia, Montenegro, Albania, Estonia, Latvia 
and Lithuania. All of these have OC less than 39 ME. In the 
other 17 countries apart from Portugal OC varies from 125 
ME (in Ireland) to 517.69 (in Germany). Southern countries 
like Italy, Greece and Spain have ME of 131.86, 155.31 and 
233.58, respectively, all above the OC in Portugal.10
CONCLUSION
 Opioid prescribing and CRP: is there an adequate 
relationship balancing between optimal use of potent 
analgesics and stable pain management? If you were to 
find a CRP undertreatment rate of 25.6% – in a sample 
of cancer patients with metastatic disease (70.9%), on 
palliative treatment (47.4%), suffering from moderate to 
severe pain (77%), and dealing with depression (75.5%) 
and anxiety (70.6%)4,5 – what would you think about? Are 
we taking the bull by the horns? We sustain: there is still 
room for improvement.
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